Pathologic upstaging and survival outcomes for patients undergoing segmentectomy versus lobectomy in clinical stage T1cN0M0 non–small cell lung cancerCentral MessagePerspective

Objectives: To assess the impact of the extent of surgical resection on overall survival in patients with clinical T1cN0M0 (cT1cN0M0) non–small cell lung cancer (NSCLC), with and without pathologic nodal upstaging (pN1+). Methods: The National Cancer Database (NCDB) was queried to identify patients...

Full description

Saved in:
Bibliographic Details
Main Authors: Ryan C. Jacobs, MD, MS, Erik E. Rabin, MD, Charles D. Logan, MD, Sandeep N. Bharadwaj, MD, Hee Chul Yang, MD, Raheem D. Bell, MD, Emily J. Cerier, MD, Chitaru Kurihara, MD, Kalvin C. Lung, MD, Diego M. Avella Patino, MD, Samuel S. Kim, MD, Ankit Bharat, MBBS
Format: Article
Language:English
Published: Elsevier 2025-04-01
Series:JTCVS Open
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2666273625000403
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850155140029349888
author Ryan C. Jacobs, MD, MS
Erik E. Rabin, MD
Charles D. Logan, MD
Sandeep N. Bharadwaj, MD
Hee Chul Yang, MD
Raheem D. Bell, MD
Emily J. Cerier, MD
Chitaru Kurihara, MD
Kalvin C. Lung, MD
Diego M. Avella Patino, MD
Samuel S. Kim, MD
Ankit Bharat, MBBS
author_facet Ryan C. Jacobs, MD, MS
Erik E. Rabin, MD
Charles D. Logan, MD
Sandeep N. Bharadwaj, MD
Hee Chul Yang, MD
Raheem D. Bell, MD
Emily J. Cerier, MD
Chitaru Kurihara, MD
Kalvin C. Lung, MD
Diego M. Avella Patino, MD
Samuel S. Kim, MD
Ankit Bharat, MBBS
author_sort Ryan C. Jacobs, MD, MS
collection DOAJ
description Objectives: To assess the impact of the extent of surgical resection on overall survival in patients with clinical T1cN0M0 (cT1cN0M0) non–small cell lung cancer (NSCLC), with and without pathologic nodal upstaging (pN1+). Methods: The National Cancer Database (NCDB) was queried to identify patients with cT1cN0M0 NSCLC who underwent lobectomy or segmentectomy without receiving neoadjuvant therapy between 2010 and 2021. Bivariate analyses were performed to compare demographic and clinical characteristics across surgical groups. Propensity score matching was used to compare outcomes of segmentectomy versus lobectomy. Cox proportional hazard models and Kaplan-Meier survival estimates were used to assess the association of overall survival on the interaction between extent of resection and pathologic nodal upstaging. Results: A total of 22,945 patients were analyzed, including 21,875 (95.3%) who underwent lobectomy and 1070 (4.7%) who underwent segmentectomy. Pathologic nodal upstaging to pN1+ occurred in 14.5% of lobectomy cases and in 6.6% of segmentectomy cases. Propensity score–matched analysis revealed that patients undergoing segmentectomy had comparable overall survival to those undergoing lobectomy (hazard ratio [HR], 1.00; 95% confidence interval [CI], 0.86-1.16), and those undergoing segmentectomy with pN1+ had comparable overall survival to those undergoing lobectomy with pN1+ (HR, 1.04; 95% CI, 0.65-1.66). Conclusions: In patients with cT1cN0M0 NSCLC, overall survival outcomes are similar between segmentectomy recipients and lobectomy recipients, including those incidentally found to have pN1+, suggesting a potential role of lobe-preserving approaches. Additionally, completion lobectomy may not offer a survival benefit in cT1cN0M0 patients incidentally discovered to have pathologic N1 nodes.
format Article
id doaj-art-d9efe924aab74f8c8cf96196af882753
institution OA Journals
issn 2666-2736
language English
publishDate 2025-04-01
publisher Elsevier
record_format Article
series JTCVS Open
spelling doaj-art-d9efe924aab74f8c8cf96196af8827532025-08-20T02:25:02ZengElsevierJTCVS Open2666-27362025-04-012439440810.1016/j.xjon.2025.01.014Pathologic upstaging and survival outcomes for patients undergoing segmentectomy versus lobectomy in clinical stage T1cN0M0 non–small cell lung cancerCentral MessagePerspectiveRyan C. Jacobs, MD, MS0Erik E. Rabin, MD1Charles D. Logan, MD2Sandeep N. Bharadwaj, MD3Hee Chul Yang, MD4Raheem D. Bell, MD5Emily J. Cerier, MD6Chitaru Kurihara, MD7Kalvin C. Lung, MD8Diego M. Avella Patino, MD9Samuel S. Kim, MD10Ankit Bharat, MBBS11Address for reprints: Ryan C. Jacobs, MD, MS, Department of Surgery, Canning Thoracic Institute, Northwestern University Feinberg School of Medicine, 676 N St Clair St, Suite 2320, Chicago, IL 60611.; Department of Surgery, Canning Thoracic Institute, Northwestern University Feinberg School of Medicine, Chicago, IllDepartment of Surgery, Canning Thoracic Institute, Northwestern University Feinberg School of Medicine, Chicago, IllDepartment of Surgery, Canning Thoracic Institute, Northwestern University Feinberg School of Medicine, Chicago, IllDepartment of Surgery, Canning Thoracic Institute, Northwestern University Feinberg School of Medicine, Chicago, IllDepartment of Surgery, Canning Thoracic Institute, Northwestern University Feinberg School of Medicine, Chicago, IllDepartment of Surgery, Canning Thoracic Institute, Northwestern University Feinberg School of Medicine, Chicago, IllDepartment of Surgery, Canning Thoracic Institute, Northwestern University Feinberg School of Medicine, Chicago, IllDepartment of Surgery, Canning Thoracic Institute, Northwestern University Feinberg School of Medicine, Chicago, IllDepartment of Surgery, Canning Thoracic Institute, Northwestern University Feinberg School of Medicine, Chicago, IllDepartment of Surgery, Canning Thoracic Institute, Northwestern University Feinberg School of Medicine, Chicago, IllDepartment of Surgery, Canning Thoracic Institute, Northwestern University Feinberg School of Medicine, Chicago, IllDepartment of Surgery, Canning Thoracic Institute, Northwestern University Feinberg School of Medicine, Chicago, IllObjectives: To assess the impact of the extent of surgical resection on overall survival in patients with clinical T1cN0M0 (cT1cN0M0) non–small cell lung cancer (NSCLC), with and without pathologic nodal upstaging (pN1+). Methods: The National Cancer Database (NCDB) was queried to identify patients with cT1cN0M0 NSCLC who underwent lobectomy or segmentectomy without receiving neoadjuvant therapy between 2010 and 2021. Bivariate analyses were performed to compare demographic and clinical characteristics across surgical groups. Propensity score matching was used to compare outcomes of segmentectomy versus lobectomy. Cox proportional hazard models and Kaplan-Meier survival estimates were used to assess the association of overall survival on the interaction between extent of resection and pathologic nodal upstaging. Results: A total of 22,945 patients were analyzed, including 21,875 (95.3%) who underwent lobectomy and 1070 (4.7%) who underwent segmentectomy. Pathologic nodal upstaging to pN1+ occurred in 14.5% of lobectomy cases and in 6.6% of segmentectomy cases. Propensity score–matched analysis revealed that patients undergoing segmentectomy had comparable overall survival to those undergoing lobectomy (hazard ratio [HR], 1.00; 95% confidence interval [CI], 0.86-1.16), and those undergoing segmentectomy with pN1+ had comparable overall survival to those undergoing lobectomy with pN1+ (HR, 1.04; 95% CI, 0.65-1.66). Conclusions: In patients with cT1cN0M0 NSCLC, overall survival outcomes are similar between segmentectomy recipients and lobectomy recipients, including those incidentally found to have pN1+, suggesting a potential role of lobe-preserving approaches. Additionally, completion lobectomy may not offer a survival benefit in cT1cN0M0 patients incidentally discovered to have pathologic N1 nodes.http://www.sciencedirect.com/science/article/pii/S2666273625000403lung cancerlobectomysegmentectomynodal stagingsurvival
spellingShingle Ryan C. Jacobs, MD, MS
Erik E. Rabin, MD
Charles D. Logan, MD
Sandeep N. Bharadwaj, MD
Hee Chul Yang, MD
Raheem D. Bell, MD
Emily J. Cerier, MD
Chitaru Kurihara, MD
Kalvin C. Lung, MD
Diego M. Avella Patino, MD
Samuel S. Kim, MD
Ankit Bharat, MBBS
Pathologic upstaging and survival outcomes for patients undergoing segmentectomy versus lobectomy in clinical stage T1cN0M0 non–small cell lung cancerCentral MessagePerspective
JTCVS Open
lung cancer
lobectomy
segmentectomy
nodal staging
survival
title Pathologic upstaging and survival outcomes for patients undergoing segmentectomy versus lobectomy in clinical stage T1cN0M0 non–small cell lung cancerCentral MessagePerspective
title_full Pathologic upstaging and survival outcomes for patients undergoing segmentectomy versus lobectomy in clinical stage T1cN0M0 non–small cell lung cancerCentral MessagePerspective
title_fullStr Pathologic upstaging and survival outcomes for patients undergoing segmentectomy versus lobectomy in clinical stage T1cN0M0 non–small cell lung cancerCentral MessagePerspective
title_full_unstemmed Pathologic upstaging and survival outcomes for patients undergoing segmentectomy versus lobectomy in clinical stage T1cN0M0 non–small cell lung cancerCentral MessagePerspective
title_short Pathologic upstaging and survival outcomes for patients undergoing segmentectomy versus lobectomy in clinical stage T1cN0M0 non–small cell lung cancerCentral MessagePerspective
title_sort pathologic upstaging and survival outcomes for patients undergoing segmentectomy versus lobectomy in clinical stage t1cn0m0 non small cell lung cancercentral messageperspective
topic lung cancer
lobectomy
segmentectomy
nodal staging
survival
url http://www.sciencedirect.com/science/article/pii/S2666273625000403
work_keys_str_mv AT ryancjacobsmdms pathologicupstagingandsurvivaloutcomesforpatientsundergoingsegmentectomyversuslobectomyinclinicalstaget1cn0m0nonsmallcelllungcancercentralmessageperspective
AT erikerabinmd pathologicupstagingandsurvivaloutcomesforpatientsundergoingsegmentectomyversuslobectomyinclinicalstaget1cn0m0nonsmallcelllungcancercentralmessageperspective
AT charlesdloganmd pathologicupstagingandsurvivaloutcomesforpatientsundergoingsegmentectomyversuslobectomyinclinicalstaget1cn0m0nonsmallcelllungcancercentralmessageperspective
AT sandeepnbharadwajmd pathologicupstagingandsurvivaloutcomesforpatientsundergoingsegmentectomyversuslobectomyinclinicalstaget1cn0m0nonsmallcelllungcancercentralmessageperspective
AT heechulyangmd pathologicupstagingandsurvivaloutcomesforpatientsundergoingsegmentectomyversuslobectomyinclinicalstaget1cn0m0nonsmallcelllungcancercentralmessageperspective
AT raheemdbellmd pathologicupstagingandsurvivaloutcomesforpatientsundergoingsegmentectomyversuslobectomyinclinicalstaget1cn0m0nonsmallcelllungcancercentralmessageperspective
AT emilyjceriermd pathologicupstagingandsurvivaloutcomesforpatientsundergoingsegmentectomyversuslobectomyinclinicalstaget1cn0m0nonsmallcelllungcancercentralmessageperspective
AT chitarukuriharamd pathologicupstagingandsurvivaloutcomesforpatientsundergoingsegmentectomyversuslobectomyinclinicalstaget1cn0m0nonsmallcelllungcancercentralmessageperspective
AT kalvinclungmd pathologicupstagingandsurvivaloutcomesforpatientsundergoingsegmentectomyversuslobectomyinclinicalstaget1cn0m0nonsmallcelllungcancercentralmessageperspective
AT diegomavellapatinomd pathologicupstagingandsurvivaloutcomesforpatientsundergoingsegmentectomyversuslobectomyinclinicalstaget1cn0m0nonsmallcelllungcancercentralmessageperspective
AT samuelskimmd pathologicupstagingandsurvivaloutcomesforpatientsundergoingsegmentectomyversuslobectomyinclinicalstaget1cn0m0nonsmallcelllungcancercentralmessageperspective
AT ankitbharatmbbs pathologicupstagingandsurvivaloutcomesforpatientsundergoingsegmentectomyversuslobectomyinclinicalstaget1cn0m0nonsmallcelllungcancercentralmessageperspective